BRPI0516704A - composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica - Google Patents

composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica

Info

Publication number
BRPI0516704A
BRPI0516704A BRPI0516704-3A BRPI0516704A BRPI0516704A BR PI0516704 A BRPI0516704 A BR PI0516704A BR PI0516704 A BRPI0516704 A BR PI0516704A BR PI0516704 A BRPI0516704 A BR PI0516704A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
preparing
producing
alkyl
Prior art date
Application number
BRPI0516704-3A
Other languages
English (en)
Inventor
Bansi Lal
Swati Bal-Tembe
Usha Ghosh
Arun Kumar Jain
Tulsidas More
Anil Ghate
Jacqueline Trivedi
Sapna Parikh
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of BRPI0516704A publication Critical patent/BRPI0516704A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, PROCESSO PARA PRODUZIR UMA COMPOSIçãO FARMACêUTICA, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO E USO DE UMA COMPOSIçãO FARMACêUTICA. A presente invenção refere-se derivados de guanidino tendo uma fórmula condensada de anel tricíclico da fórmula 1: 1: são revelados, nos quais U é C (O), CR¬ a¬R¬ b¬, O, NR¬ a¬ ou S(O)~ m~; V é CR¬ a¬R¬ b¬ ou NR¬ a¬ ; W é S(O)~ m~; nos quais R¬ a¬ é H, alquila, cicloalquila, alquenila ou aralquila; R¬ b¬ é H, alquila, OH, OR¬ a¬ ou OCOR¬ a¬, e é o número inteiro 0, 1 ou 2; R1, R2, R3, R4, R5, R6, R7 e R8 são conforme aqui definidos com a provisão que pelo menos um dos R1, R2, R3, R4, R5, R6, R7 ou R8 é quanidino ou guanidino carbonila. Esses derivativos são inibidores da troca de sódio - proton e são úteis como medicamentos para o tratamento de, por exemplo, desordens de órgãos associadas com isquemia e reperfusão, arritmia cardíaca, hipertrofia cardíaca, hipertensão, desordens de proliferação de células e diabetes.
BRPI0516704-3A 2004-11-10 2005-11-08 composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica BRPI0516704A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1225MU2004 2004-11-10
US63720804P 2004-12-17 2004-12-17
PCT/IB2005/053653 WO2006051476A1 (en) 2004-11-10 2005-11-08 Tricyclic guanidine derivatives as sodium-proton exchange inhibitors

Publications (1)

Publication Number Publication Date
BRPI0516704A true BRPI0516704A (pt) 2008-09-16

Family

ID=38006671

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516704-3A BRPI0516704A (pt) 2004-11-10 2005-11-08 composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica

Country Status (16)

Country Link
US (2) US7834001B2 (pt)
EP (1) EP1812420A1 (pt)
JP (1) JP4921375B2 (pt)
KR (1) KR20070106980A (pt)
CN (2) CN102952112A (pt)
AR (1) AR053312A1 (pt)
AU (1) AU2005303409B2 (pt)
BR (1) BRPI0516704A (pt)
CA (1) CA2587620A1 (pt)
IL (1) IL183086A0 (pt)
MX (1) MX2007005469A (pt)
NZ (1) NZ554936A (pt)
RU (1) RU2390521C2 (pt)
TW (1) TW200614995A (pt)
WO (1) WO2006051476A1 (pt)
ZA (1) ZA200703756B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
MX2013008827A (es) * 2011-02-02 2014-02-10 Astellas Pharma Inc Derivado de tetrahidroisoquinolina.
RU2558087C2 (ru) * 2013-10-22 2015-07-27 Сергей Владимирович Шумилин Способ управления нефтегазовым месторождением
RU2558088C2 (ru) * 2013-10-23 2015-07-27 Сергей Владимирович Шумилин Способ управления нефтегазовой скважиной
EP3587391A1 (en) 2018-06-22 2020-01-01 Basf Se Process for preparing nitrobenzyl bromides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2094790B (en) * 1981-03-13 1985-10-09 Spofa Vereinigte Pharma Werke Tricycle compounds
US5036067A (en) * 1990-03-14 1991-07-30 Merck & Co., Inc. Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
ATE147375T1 (de) * 1992-09-22 1997-01-15 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, sowie ihre verwendung als antiarrhythmika
DE4437874A1 (de) * 1994-10-22 1996-04-25 Merck Patent Gmbh Alkyl-5-methylsulfonyl-benzoylguanidin-Derivate
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JPH10152481A (ja) * 1996-09-25 1998-06-09 Kanebo Ltd ベンゾ［１，４］チアジン誘導体およびそれからなる医薬
FR2765580B1 (fr) 1997-07-01 1999-08-06 Synthelabo Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique
JP2002542291A (ja) * 1999-04-23 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー ジ環式アシルグアニジン・ナトリウム／プロトン交換抑制剤および方法
DE10204989A1 (de) * 2002-02-07 2003-08-21 Aventis Pharma Gmbh Dihydro-thia-phenanthren-carbonyl-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
JP4921375B2 (ja) 2012-04-25
CA2587620A1 (en) 2006-05-18
TW200614995A (en) 2006-05-16
MX2007005469A (es) 2007-07-10
RU2390521C2 (ru) 2010-05-27
IL183086A0 (en) 2007-09-20
RU2007121681A (ru) 2008-12-20
JP2008519823A (ja) 2008-06-12
NZ554936A (en) 2010-09-30
KR20070106980A (ko) 2007-11-06
CN102952112A (zh) 2013-03-06
EP1812420A1 (en) 2007-08-01
CN101076526A (zh) 2007-11-21
AU2005303409A1 (en) 2006-05-18
AR053312A1 (es) 2007-05-02
US8183234B2 (en) 2012-05-22
US7834001B2 (en) 2010-11-16
WO2006051476A1 (en) 2006-05-18
ZA200703756B (en) 2008-06-25
AU2005303409B2 (en) 2011-12-15
US20100267690A1 (en) 2010-10-21
US20070299051A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
BRPI0516704A (pt) composto, processo para a preparação de um composto, processo para produzir uma composição farmacêutica, composição farmacêutica, uso de um composto e uso de uma composição farmacêutica
BRPI0607817A2 (pt) processo para a preparação de compostos macrocìclicos
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
AR035885A1 (es) Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BRPI0610030B8 (pt) Composto, composição farmacêutica, e, uso de um composto
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR036213A1 (es) Derivados de 6-fenil-pirrolo[2,3-d]pirimidina, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de composiciones farmaceuticas
EA200401609A1 (ru) Лекарственное средство для лечения диабета
ATE283259T1 (de) 1,4-substituierte cyclische aminderivate
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
BR0311556A (pt) Derivados de n-((3-oxo-2,3-diidro-1h-isoindol-1-il)acetil)guanidina como inibidores de nhe-1 para o tratamento de enfarte e angina pectoris
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
BR0309748A (pt) Derivados de n-acil piperidina e composição compreendendo os mesmos
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
BR0314966A (pt) Processo para preparar um composto, e, composto
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: NICHOLAS PIRAMAL INDIA LIMITED (IN)

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100053599/RJ DE 15/06/2010, E NECESSARIO APRESENTAR A DOCUMENTACAO COM A DEVIDA LEGALIZACAO CONSULAR, ALEM DE GUIA REFERENTE A UMA ALTERACAO DE NOME, BEM COMO A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25B Requested transfer of rights rejected

Owner name: NICHOLAS PIRAMAL INDIA LIMITED (IN)

Free format text: INDEFERIDA A TRANSFERENCIA SOLICITADA ATRAVES DA PETICAO NO 020100053599/RJ DE 15/06/2010, POR FALTA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2110 DE 14/06/2011.

B25D Requested change of name of applicant approved

Owner name: PIRAMAL HEALTHCARE LIMITED (IN)

Free format text: NOME ALTERADO DE: NICHOLAS PIRAMAL INDIA LIMITED

B25G Requested change of headquarter approved

Owner name: PIRAMAL HEALTHCARE LIMITED (IN)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110084023/RJ DE 11/08/2011.

B25A Requested transfer of rights approved

Owner name: PIRAMAL LIFE SCIENCES LIMITED (IN)

Free format text: TRANSFERIDO DE: PIRAMAL HEALTHCARE LIMITED

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2280 DE 16/09/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 10 DA RESOLUCAO 113/2013, REFERENTE AO NAO RECOLHIMENTO DA 8A A 15A RETRIBUICAO ANUAL, PARA FINS DE RESTAURACAO CONFORME ARTIGO 87 DA LPI 9.279, SOB PENA DA MANUTENCAO DO ARQUIVAMENTO CASO NAO SEJA RESTAURADO DENTRO DO PRAZO LEGAL, CONFORME O DISPOSTO NO ARTIGO 12 DA RESOLUCAO 113/2013.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2611 DE 19-01-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.